|
1
|
Sauer R, Becker H, Hohenberger W, et al:
Preoperative versus postoperative chemoradiotherapy for rectal
cancer. N Eng J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bosset JF, Collette L, Calais G, et al:
Chemotherapy with preoperative radiotherapy in rectal cancer. N Eng
J Med. 355:1114–1123. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ortholan C, Francois E, Thomas O, et al:
Role of radiotherapy with surgery for T3 and resectable T4 rectal
cancer: evidence from randomized trials. Dis Colon Rectum.
49:302–310. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Debucquoy A, Goethals L, Geboes K, Roels
S, Mc Bride WH and Haustermans K: Molecular responses of rectal
cancer to preoperative chemoradiation. Radiother Oncol. 80:172–177.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Baier PK, Eggstein S, Wolff-Vorbeck G,
Baumgartner U and Hopt UT: Chemokines in human colorectal
carcinoma. Anticancer Res. 25:3581–3584. 2005.PubMed/NCBI
|
|
6
|
Dranoff G: Cytokines in cancer
pathogenesis and cancer therapy (Review). Nat Rev Cancer. 4:11–22.
2004. View
Article : Google Scholar
|
|
7
|
Okita R, Yamaguchi Y, Ohara M, et al:
Targeting of CD4+CD25high cells while
preserving CD4+CD25low cells with low-dose
chimeric anti-CD25 antibody in adoptive immunotherapy of cancer.
Int J Oncol. 34:563–572. 2009.
|
|
8
|
Ostrand-Rosenberg S: Myeloid-derived
suppressor cells: more mechanisms for inhibiting antitumor immunity
(Review). Cancer Immunol Immunother. 59:1593–1600. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McDonnell AM, Nowak AK and Lake RA:
Contribution of the immune system to the chemotherapeutic response.
Semin Immunopathol. 33:353–367. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ong ZY, Gibson RJ, Bowen JM, et al:
Pro-inflammatory cytokines play a key role in the development of
radiotherapy-induced gastrointestinal mucositis. Radiat Oncol.
5:222010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schaue D, Kachikwu EL and McBride WH:
Cytokines in radiobiological responses: a review (Review). Radiat
Res. 178:505–523. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin WW and Karin M: A cytokine-mediated
link between innate immunity, inflammation, and cancer. J Clin
Invest. 117:1175–1183. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin CC, Liu CY, Chen MJ, et al: Profiles
of circulating endothelial cells and serum cytokines during
adjuvant chemoradiation in rectal cancer patients. Clin Transl
Oncol. 15:855–860. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chung YC and Chang YF: Serum interleukin-6
levels reflect the disease status of colorectal cancer. J Surg
Oncol. 83:222–226. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Waldner MJ, Foersch S and Neurath MF:
Interleukin-6 - a key regulator of colorectal cancer development.
Int J Biol Sci. 8:1248–1253. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lopes CO and Callera F: Three-dimensional
conformal radiotherapy in prostate cancer patients: rise in
interleukin 6 (IL-6) but not IL-2, IL-4, IL-5, tumor necrosis
factor-α, MIP-1-α, and LIF levels. Int J Radiat Oncol Biol Phys.
82:1385–1388. 2012.PubMed/NCBI
|
|
17
|
Andre P, Nannizzi-Alaimo L, Prasad SK and
Phillips DR: Platelet-derived CD40L: the switch-hitting player of
cardiovascular disease. Circulation. 106:896–899. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aukrust P, Damas JK and Solum NO: Soluble
CD40 ligand and platelets: self-perpetuating pathogenic loop in
thrombosis and inflammation? J Am Coll Cardiol. 43:2326–2328. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schlom J, Jochems C, Gulley JL and Huang
J: The role of soluble CD40L in immunosuppression. Oncoimmunology.
2:e225462013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang J, Jochems C, Talaie T, et al:
Elevated serum soluble CD40 ligand in cancer patients may play an
immunosuppressive role. Blood. 120:3030–3038. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schlecker E, Stojanovic A, Eisen C, et al:
Tumor-infiltrating monocytic myeloid-derived suppressor cells
mediate CCR5-dependent recruitment of regulatory T cells favoring
tumor growth. J Immunol. 189:5602–5611. 2012. View Article : Google Scholar
|
|
22
|
Umekawa K, Kimura T, Kudoh S, et al:
Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer
patients treated with EGFR-TKIs. BMC Res Notes. 6:1392013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin S, Wan S, Sun L, et al: Chemokine C-C
motif receptor 5 and C-C motif ligand 5 promote cancer cell
migration under hypoxia. Cancer Sci. 103:904–912. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chuang JY, Yang WH, Chen HT, et al:
CCL5/CCR5 axis promotes the motility of human oral cancer cells. J
Cell Physiol. 220:418–426. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lapteva N and Huang XF: CCL5 as an
adjuvant for cancer immunotherapy. Expert Opin Biol Ther.
10:725–733. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Y, Yao F, Yao X, et al: Role of CCL5
in invasion, proliferation and proportion of
CD44+/CD24− phenotype of MCF-7 cells and
correlation of CCL5 and CCR5 expression with breast cancer
progression. Oncol Rep. 21:1113–1121. 2009.PubMed/NCBI
|
|
27
|
Yi EH, Lee CS, Lee JK, et al: STAT3-RANTES
autocrine signaling is essential for tamoxifen resistance in human
breast cancer cells. Mol Cancer Res. 11:31–42. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Radziwon-Balicka A, Medina C, O'Driscoll
L, et al: Platelets increase survival of adenocarcinoma cells
challenged with anticancer drugs: mechanisms and implications for
chemoresistance. Br J Pharmacol. 167:787–804. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li R, Chen WC, Pang XQ, Hua C, Li L and
Zhang XG: Expression of CD40 and CD40L in gastric cancer tissue and
its clinical significance. Int J Mol Sci. 10:3900–3917. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Roselli M, Mineo TC, Basili S, et al:
Soluble CD40 ligand plasma levels in lung cancer. Clin Cancer Res.
10:610–614. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pan W, Gong J, Yang C, et al: Peripheral
blood CD40-CD40L expression in human breast cancer. Ir J Med Sci.
Feb 28–2013.(Epub ahead of print).
|
|
32
|
Toutirais O, Gervais A, Cabillic F, et al:
Effects of CD40 binding on ovarian carcinoma cell growth and
cytokine production in vitro. Clin Exp Immunol. 149:372–377. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li R, Chen WC, Pang XQ, Tian WY and Zhang
XG: Influence of sCD40L on gastric cancer cell lines. Mol Biol Rep.
38:5459–5464. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mathur RK, Awasthi A, Wadhone P,
Ramanamurthy B and Saha B: Reciprocal CD40 signals through p38MAPK
and ERK-1/2 induce counteracting immune responses. Nat Med.
10:540–544. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Becker C, Fantini MC, Wirtz S, et al: IL-6
signaling promotes tumor growth in colorectal cancer. Cell Cycle.
4:217–220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ardestani S, Li B, Deskins DL, Wu H,
Massion PP and Young PP: Membrane versus soluble isoforms of TNF-α
exert opposing effects on tumor growth and survival of
tumor-associated myeloid cells. Cancer Res. 73:3938–3950.
2013.PubMed/NCBI
|
|
37
|
Ferroni P, Riondino S, Portarena I, et al:
Association between increased tumor necrosis factor alpha levels
and acquired activated protein C resistance in patients with
metastatic colorectal cancer. Int J Colorectal Dis. 27:1561–1567.
2012. View Article : Google Scholar
|
|
38
|
Kawai K, Kitayama J, Tsuno NH, Sunami E
and Watanabe T: Thrombocytosis before pre-operative
chemoradiotherapy predicts poor response and shorter local
recurrence-free survival in rectal cancer. Int J Colorectal Dis.
28:527–535. 2013. View Article : Google Scholar
|
